Endogenous neurotensin attenuates dopamine-dependent locomotion and stereotypy

Brain Res. 2004 Oct 1;1022(1-2):71-80. doi: 10.1016/j.brainres.2004.06.061.

Abstract

The neuropeptide neurotensin (NT) is highly sensitive to changes in dopaminergic signaling in the striatum, and is thought to modulate dopamine-mediated behaviors. To explore the interaction of NT with the dopamine system, we utilized mice with a targeted deletion of dopamine synthesis specifically in dopaminergic neurons. Dopamine levels in dopamine-deficient (DD) mice are less than 1% of control mice, and they require daily administration of the dopamine precursor L-dihydroxyphenylalanine (L-DOPA) for survival. DD mice are supersensitive to the effects of dopamine, becoming hyperactive relative to control mice in the presence of L-DOPA. We show that 24 h after L-DOPA treatment, when DD mice are in a "dopamine-depleted" state, Nt mRNA levels in the striatum of DD mice are similar to those in control mice. Administration of L-DOPA or L-DOPA plus the L-amino acid decarboxylase inhibitor, carbidopa, (C/L-DOPA) induced Nt expression in the striatum of DD mice. The dopamine D1 receptor antagonist, SCH23390, blocked C/L-DOPA-induced Nt. To test the hypothesis that this striatal Nt expression modulated dopamine-mediated behavior in DD mice, we administered SR 48692, an antagonist of the high affinity NT receptor, together with L-DOPA or C/L-DOPA. L-DOPA-induced hyperlocomotion and C/L-DOPA-induced stereotypy were potentiated by peripheral administration of SR 48692. Furthermore, intrastriatal microinjections of SR 48692 augmented L-DOPA-induced hyperlocomotion. These results demonstrate a dynamic regulation of striatal Nt expression by dopamine via D1 receptors in DD mice, and point to a physiological role for endogenous striatal NT in counteracting motor behaviors induced by an overactive dopamine system.

Publication types

  • Comparative Study
  • Research Support, N.I.H., Extramural

MeSH terms

  • Age Factors
  • Animals
  • Behavior, Animal
  • Benzazepines / pharmacology
  • Carbidopa / pharmacology
  • Corpus Striatum / drug effects
  • Corpus Striatum / metabolism
  • Dopamine / pharmacology
  • Dopamine / physiology*
  • Dopamine Agents / pharmacology
  • Dopamine Antagonists / pharmacology
  • Dopamine beta-Hydroxylase / deficiency
  • Dose-Response Relationship, Drug
  • Drug Interactions
  • Enzyme Inhibitors / metabolism
  • Female
  • Gene Expression / physiology
  • Haloperidol / pharmacology
  • In Situ Hybridization / methods
  • Levodopa / pharmacology
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mice, Transgenic
  • Motor Activity / drug effects
  • Motor Activity / physiology*
  • Neurotensin / genetics
  • Neurotensin / metabolism*
  • Pyrazoles / pharmacology
  • Quinolines / pharmacology
  • RNA, Messenger / metabolism
  • Receptors, Neurotensin / antagonists & inhibitors
  • Stereotyped Behavior / drug effects
  • Stereotyped Behavior / physiology*
  • Time Factors
  • Tyrosine 3-Monooxygenase / deficiency

Substances

  • Benzazepines
  • Dopamine Agents
  • Dopamine Antagonists
  • Enzyme Inhibitors
  • Pyrazoles
  • Quinolines
  • RNA, Messenger
  • Receptors, Neurotensin
  • SR 48692
  • Neurotensin
  • Levodopa
  • Tyrosine 3-Monooxygenase
  • Dopamine beta-Hydroxylase
  • Haloperidol
  • Carbidopa
  • Dopamine